Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by ...

The Eden Rose Foundation was founded in 2022 after Tyler and Molly Lockard of Worland, Wyo. lost their newborn Eden Rose ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.

Current drugs available for the treatment of primary arterial hypertension ... has been associated with persistent pulmonary hypertension of the newborn.

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a ...

In November 2024, MSD’s Winrevair (sotatercept-csrk) met the primary endpoint in a Phase III trial in patients with pulmonary ...